Zacks: Brokerages Expect CVS Health Co. (NYSE:CVS) to Announce $1.69 EPS


Share on StockTwits

Wall Street brokerages predict that CVS Health Co. (NYSE:CVS) will announce earnings of $1.69 per share for the current quarter, Zacks Investment Research reports. Seven analysts have provided estimates for CVS Health’s earnings, with estimates ranging from $1.49 to $1.77. CVS Health posted earnings of $1.91 per share in the same quarter last year, which would suggest a negative year over year growth rate of 11.5%. The business is scheduled to issue its next quarterly earnings report on Wednesday, May 5th.

On average, analysts expect that CVS Health will report full-year earnings of $7.52 per share for the current financial year, with EPS estimates ranging from $7.41 to $7.83. For the next financial year, analysts anticipate that the business will post earnings of $8.05 per share, with EPS estimates ranging from $6.68 to $8.38. Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that cover CVS Health.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Monday, February 15th. The pharmacy operator reported $1.30 EPS for the quarter, topping analysts’ consensus estimates of $1.24 by $0.06. CVS Health had a net margin of 2.99% and a return on equity of 15.60%. The business had revenue of $69.55 billion for the quarter, compared to analysts’ expectations of $68.67 billion. During the same quarter last year, the company earned $1.73 EPS.

CVS has been the topic of a number of analyst reports. Jefferies Financial Group upgraded CVS Health from a “hold” rating to a “buy” rating and set a $90.00 target price on the stock in a research report on Friday, January 8th. Guggenheim reissued a “neutral” rating on shares of CVS Health in a report on Tuesday, March 23rd. Finally, SVB Leerink upped their target price on CVS Health from $73.00 to $80.00 and gave the stock a “market perform” rating in a research note on Monday, December 14th. Four research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $82.08.

CVS traded down $0.32 on Thursday, reaching $74.17. The stock had a trading volume of 19,258 shares, compared to its average volume of 7,071,797. The business’s 50-day moving average price is $72.43 and its two-hundred day moving average price is $68.51. The company has a current ratio of 0.95, a quick ratio of 0.67 and a debt-to-equity ratio of 0.89. CVS Health has a 12-month low of $55.36 and a 12-month high of $77.23. The company has a market cap of $97.26 billion, a P/E ratio of 12.24, a price-to-earnings-growth ratio of 1.72 and a beta of 0.82.

The firm also recently announced a quarterly dividend, which will be paid on Monday, May 3rd. Shareholders of record on Friday, April 23rd will be paid a dividend of $0.50 per share. The ex-dividend date is Thursday, April 22nd. This represents a $2.00 annualized dividend and a yield of 2.70%. CVS Health’s dividend payout ratio (DPR) is presently 28.25%.

In other CVS Health news, SVP James David Clark sold 5,350 shares of the firm’s stock in a transaction that occurred on Wednesday, March 31st. The shares were sold at an average price of $76.00, for a total value of $406,600.00. Also, EVP Thomas M. Moriarty sold 49,211 shares of the business’s stock in a transaction that occurred on Friday, March 19th. The stock was sold at an average price of $74.15, for a total value of $3,648,995.65. Following the transaction, the executive vice president now owns 12,778 shares in the company, valued at $947,488.70. The disclosure for this sale can be found here. Insiders have sold 594,375 shares of company stock valued at $44,673,602 in the last ninety days. Insiders own 0.46% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of CVS. First Trust Advisors LP increased its position in CVS Health by 1.2% during the fourth quarter. First Trust Advisors LP now owns 1,320,232 shares of the pharmacy operator’s stock worth $90,172,000 after purchasing an additional 15,828 shares during the last quarter. Kingfisher Capital LLC raised its position in shares of CVS Health by 7.7% during the 4th quarter. Kingfisher Capital LLC now owns 21,834 shares of the pharmacy operator’s stock valued at $1,491,000 after buying an additional 1,569 shares during the period. Pzena Investment Management LLC lifted its holdings in CVS Health by 6.5% in the fourth quarter. Pzena Investment Management LLC now owns 1,233,975 shares of the pharmacy operator’s stock valued at $84,280,000 after acquiring an additional 75,581 shares during the last quarter. Madison Wealth Management grew its position in CVS Health by 41.3% in the fourth quarter. Madison Wealth Management now owns 85,514 shares of the pharmacy operator’s stock worth $5,841,000 after acquiring an additional 24,995 shares during the period. Finally, Norges Bank acquired a new stake in CVS Health during the fourth quarter worth $964,912,000. 74.21% of the stock is owned by institutional investors and hedge funds.

About CVS Health

CVS Health Corporation provides health services in the United States. The company's Pharmacy Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, clinical, and disease and medical spend management services.

Featured Story: How to track put option volume

Get a free copy of the Zacks research report on CVS Health (CVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.